Molecular Therapeutics Research Program Archives

Chad Pecot, MD, and Kristina Whately, PhD, work in the Pecot Lab.

Chad Pecot, MD, leads cancer RNA research at UNC Lineberger, creating innovative therapies and promising treatment strategies for multiple cancer mutations.

Headshots of Sarah Cohen, Marissa Hall, and Lindsey James.

Three UNC Lineberger members will share their research during the Het Talks at UNC-Chapel Hill’s University Research Week, Oct. 20-24.

Headshots of Victoria Bae-Jump, MD, PhD, and Hazel Nichols, PhD.

The National Cancer Institute has awarded a Cancer Health Disparities Specialized Program of Research Excellence (SPORE) in Endometrial Cancer grant to UNC Lineberger's Victoria Bae-Jump, MD, PhD, and Hazel Nichols, PhD.

UNC Lineberger has launched a first-of-its-kind clinical trial aimed at improving outcomes in BRAF wildtype anaplastic thyroid cancer (ATC). Siddharth Sheth, DO, MPH, and Jeffrey Blumberg, MD, FACS, are leading the trial.

Schematic of an EGFR targeting ligand, linked to a dual targeting KRAS and MYC chimera molecule.

Chad Pecot, MD, and colleagues have developed a “two-in-one” molecule that targets hard-to-treat cancers by silencing two key genes — KRAS and MYC — while also delivering drugs directly to affected tumors.

Sarah Cohen, PhD, Marissa Hall, PhD, and Lindsey James, PhD, were awarded Hettleman Prizes, which recognizes UNC-Chapel Hill early-career faculty who exemplify groundbreaking and innovative research.

Single strand ribonucleic acid, RNA research and therapy.

Chad Pecot, MD, and colleagues have demonstrated that a uniquely engineered drug that zeroes in on a mutated gene called KRAS G12V could potentially stop KRAS-dependent cancers in their tracks.

Two cancer researchers in a lab holding a slide to view under a microscope.

The American Association of Cancer Research has designated May as National Cancer Research Month to help underscore the importance and impact of cancer research.

UNC Lineberger researchers and colleagues have discovered an important overlap in genes regulated by the activity of three proteins that support the growth of pancreatic cancer.

Tag: Molecular Therapeutics Research Program

‘If you’re trying to make a difference in cancer, you can’t go slow’

UNC Lineberger faculty members presenting Het Talks during University Research Week

Researchers awarded $11.2M grant to close endometrial cancer survival gap

UNC Lineberger launches groundbreaking trial for rare, aggressive thyroid cancer

New molecular technology targets tumors and simultaneously silences two ‘undruggable’ cancer genes

UNC honors three cancer center members with 2025 Hettleman Prizes

Uniquely engineered KRAS-targeted cancer drug found to be effective in early studies

North Carolina Health News: Father’s death led UNC researcher to seek treatments for pancreatic cancer

UNC Lineberger commemorates National Cancer Research Month

New drug combinations found to potentially be more effective in targeting pancreatic cancers